AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01837810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800mg every 8 hours as needed for pain
Study NCT02182700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol sulfate + ipratropium bromide
Description: 120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
Study NCT00947388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
Study NCT00947388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
Study NCT00673114 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: haplo/cord transplant
Description: T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
Study NCT02765971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gums
Description: Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
Study NCT02765971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picolax drops
Description: Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
Study NCT02765971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group C received 500 cc of normal saline, Intravenous fluid
Study NCT02576769 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03368573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QbTest
Description: QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
Study NCT02201511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-06412562 MR tablets_Fasted
Description: A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
Study NCT02201511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 15 mg PF-06412562 MR tablets_Fasted
Description: Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
Study NCT02201511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 15 mg PF-06412562 MR tablets_Fed
Description: Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
Study NCT02201511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PF-06412562 IR tablets
Description: a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
Study NCT00423696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00423696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00423696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00423696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00423696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00539721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 3
Description: Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study NCT00539721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 4
Description: 200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study NCT02125773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed Risk Score
Description: Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
Study NCT03340428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Community Adherence Club (TCAC)
Description: A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
Study NCT03849755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PEPPER system
Description: The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
Study NCT03411837 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dupilumab
Description: Biologic (monoclonal antibody)
Study NCT00539721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
Study NCT04520269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
Study NCT00539721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study NCT00174941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
Study NCT00174941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
Study NCT00174941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
Study NCT04952012 — intervention group
Intervention type: DRUG
Intervention: LT4
Description: LT4 is used to improve the thyroid function of pregnant women.
Study NCT05784792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lugol -
Description: Patients that undergo total thyroidectomy without Lugol solution pretreatment
Study NCT04763265 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A BoNT/A-DP
Description: To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
Study NCT04763265 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A Botox Cosmetics
Description: To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
Study NCT01755481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT01755481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Study NCT00283712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
Study NCT00283712 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo administered in place of infliximab for control group
Study NCT02429648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCC first then PVI
Description: DCC performed prior to PVI
Study NCT02429648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI then DCC after
Description: DCC performed after PVI, if patient remains in Atrial Fibrillation
Study NCT03126227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101
Description: AR101 powder provided in capsules
Study NCT03126227 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder provided in capsules
Study NCT04252417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: Single oral dose administration of MD1003 at Day 1
Study NCT01598181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS NeuroConn DC-stimulator plus
Description: Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
Study NCT01598181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS NeuroConn DC-stimulator plus
Description: Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
Study NCT01598181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: similar montage and time as active. Stimulation fades out after 20 sec.
Study NCT03569007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Larazotide
Description: Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
Study NCT03273153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
Study NCT03273153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg as IV infusion once in every 2 weeks.
Study NCT03273153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
Study NCT02012335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECT + Ketamine
Description: Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
Study NCT03004703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
Study NCT03004703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
Study NCT00819312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ (SH T00186, BAY86-5300)
Description: 20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Study NCT03542669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6B11-OCIK Injection
Description: Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
Study NCT03542669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
Study NCT00636129 — intervention group
Intervention type: BEHAVIORAL
Intervention: Relaxation Response + Stress Management Curriculum
Description: Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
Study NCT00264108 — intervention group
Intervention type: DRUG
Intervention: Darbepoetin alfa
Description: Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
Study NCT00264108 — intervention group
Intervention type: DRUG
Intervention: Epoetin alfa
Description: 40,000 IU once weekly, variable treatment length.
Study NCT01537887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally once daily for 10 days.
Study NCT01537887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 10 days.
Study NCT01537887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose administered orally.
Study NCT03559569 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological samples will be done to evaluate the endothelial and leukocyte senescence.
Description: Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
Study NCT03537482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 will be administered as an oral tablet
Study NCT00834275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg Capsules
Description: 1 x 500 mg
Study NCT00217438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00217438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: Given IV
Study NCT00217438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV
Study NCT00217438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amifostine trihydrate
Description: Given IV
Study NCT00834275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DURICEF® capsules 500 mg
Description: 1 x 500 mg
Study NCT03599362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Cabiralizumab
Description: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
Study NCT03599362 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
Study NCT05456763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sodium butyrate
Description: add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
Study NCT03569007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: enteric-coated beads in gelatin capsules
Study NCT03144635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir plus Elbasvir
Description: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
Study NCT01716156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
Study NCT05456763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04547192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving initial care of the injured
Description: Improvement in Care Processes
Study NCT00798603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00798603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00798603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT02742558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cholvax
Description: Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
Study NCT02742558 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
Study NCT04049760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl 150 mg
Description: migalastat HCl 150 mg capsule
Study NCT02466451 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT00217438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04183335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT03827395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEV 239
Description: Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
Study NCT03827395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
Study NCT04193241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of chest tube wound
Description: At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
Study NCT04193241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of chest tube wound
Description: At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
Study NCT03934281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honey dressing Melectis G
Description: The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended.
Study NCT03934281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HAS recommendation dressing
Description: Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended.